Clinical trial · no report yet · Phase 3
EvoPAR-BR01
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- NCT06380751 ↗
- Recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- Saruparib (AZD5305); Camizestrant; Abemaciclib; Ribociclib; Palbociclib; Fulvestrant; Letrozole; Anastrozole; Exemestane
- Arms
- Arm 1: saruparib (AZD5305) plus camizestrant · Experimental
- Arm 2: Physician's choice CDK4/6i plus physician's choice ET · Active comparator
- Arm 3: Physician's choice CDK4/6i plus camizestrant · Experimental
- Arm 4: Saruparib (AZD5305) plus physician's choice ET · Experimental
- Enrollment
- 788 (estimated)
- Primary outcomes
- Progression-Free Survival (Arm 1 vs arm 2)
- Sponsor
- AstraZeneca
- Start
- Aug 1, 2024
- Primary completion
- Dec 18, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06380751 · updated Sep 2, 2026